Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer Reports Solid Q4 Earnings But Offers Weaker Outlook Stock undervalued as recent weak performance doesn’t reflect long-term outlook.

Pfizer Inc. raised the lower end of its earnings forecast for the year and reiterated its sales expectations despite unfavorable currency trends. The drugmaker continues to project its new Covid ...

Pfizer (PFE) is set to release its Q4 2023 results amid rising bearish bets on its earnings outlook due to headwinds against its COVID-19 franchise. Read more here.

Pfizer reported third-quarter revenue and adjusted profit that blew past expectations. The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales ...

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

Pfizer's Q3 adjusted earnings of $1.78 per share easily beat estimates. The drugmaker raised its annual outlook for earnings and COVID-19 vaccine sales. Pfizer is counting on acquisitions and its ...

Pfizer said Tuesday it now expects 2024 adjusted earnings between $2.45 a share to $2.65 a share, 30 cents higher at the midpoint than its prior projection. The shares rose as much as 1.4% at the ...

Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

We think PFE stock may see higher levels post Q3 announcement on a revenue and earnings beat. If the company were to raise its full-year outlook, it will likely bode well with the investors.